BioWorld Asia

May 12, 2004

Arpida Raises CHF51.3M, Plans To Move Iclaprim Into Phase III

Arpida Ltd. raised CHF51.3 million (US$39.4 million) in a Series C funding round, bringing its total funding to date to CHF105 million. (BioWorld International) Read More

Faust Pharmaceuticals Closes EUR16M Second-Round Financing

Molecular Switch That Triggers Apoptosis Delivers Drug Target

Eirx Out-Licenses Apoptosis Targets To OSI In $18.8M Deal

Lectus Gets Investment From Takeda For PFD Protein Work

Report: 25 Recommendations For EU Strategies On Genetic Testing

Immatics Raises EUR8.5M In First Round Of Financing

Advanced Biotherapy Cross-Licenses IP With Innogenetics

Biota Holdings Suing GSK Over Support For Flu Drug

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 29, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 29, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...